USD
Reduce targetBefore 30.05%Target 30%
Cash allocation. No separate rationale was supplied.
Strategy decision
Loading the recorded decision…
Targets, reasoning, and execution evidence will appear here.
Strategy decision
Targets, reasoning, and execution evidence will appear here.
Strategy decision
Sep 18, 2026, 8:08 AM EDT
Using this strategy in your portfolio? Open the Builder to review its source targets. Review your saved portfolio →
The decision
A 30% cash reserve keeps the umbrella open while spreading the remaining capital evenly across ten defensive holdings. The mix favors supplied evidence of income, reasonable valuations where available, and stable-to-improving 20-session behavior, while avoiding a heroic bet on any one patch of weather. We retain weaker recent price action only at measured weights where the defensive sleeve and income evidence still earn a seat.
Targets & reasoning
Before is the portfolio weight captured at decision time. Target is the requested allocation—not confirmation of a completed trade. These are simulated strategy weights, not personalized allocations.
Cash allocation. No separate rationale was supplied.
I expect AES to add income and modest recovery potential because its 4.74% trailing dividend yield, 7.35 P/E, and positive 1.02% 20-session return are unusually supportive for this sleeve. I exit if the recent positive price behavior reverses materially and the value case ceases to compensate.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: high · Horizon: months
I expect CI to provide a value-oriented healthcare-services sleeve because its 10.94 P/E is the lowest supplied among the larger managed-care choices and its 20-session decline was limited to 0.52%. I exit if the mild weakness broadens and valuation support fails to contain downside.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: high · Horizon: quarters
I expect ED to provide a steadier utility anchor because its 3.28% trailing dividend yield and 14.53 P/E support the defensive sleeve, while its 20-session return was only -0.85%. I'm wrong if the modest recent weakness accelerates and undermines its stabilizing role.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: medium · Horizon: quarters
I expect ELV to contribute healthcare resilience and total-return participation because it produced a 3.97% 20-session gain while trading at a 14.93 P/E. I'm wrong if this improving price behavior fades and the valuation no longer distinguishes it from the defensive alternatives.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: high · Horizon: quarters
I expect GILD to supply a balanced healthcare allocation because its price is above its 20-session average and its 20-session return is 2.23%, alongside a 2.15% trailing dividend yield. I exit if the positive short-term trend breaks without income evidence offsetting the deterioration.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: medium · Horizon: months
I expect HCA to add measured healthcare growth because its 5.40% 20-session return is the strongest supplied result in the group and its 15.66 P/E remains moderate. I'm wrong if that price strength reverses sharply, leaving the low 0.71% dividend yield without a compensating return engine.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: high · Horizon: months
I expect KO to remain a defensive staple ballast because it offers a 2.38% trailing dividend yield and reported positive vendor evidence of sales and EPS growth, despite a 2.53% 20-session decline. I'm wrong if the recent softness persists and the supplied operating momentum no longer supports resilience.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: medium · Horizon: quarters
I expect MO to contribute income and diversification because its 6.15% trailing dividend yield and 5.56% 20-session return provide the strongest supplied staple income-and-momentum combination. I'm wrong if the cited long-term business risk around declining cigarette shipments overwhelms that income support.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: medium · Horizon: months
I expect PEP to offer a measured contrarian staples allocation because its 4.34% trailing dividend yield and 19.95 P/E provide income and a less demanding valuation than some peers after a 6.26% 20-session decline. I exit if the decline continues and the dividend case fails to stabilize returns.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: medium · Horizon: quarters
I expect PG to provide dependable staples exposure because its price stands above its 20-session average, its 20-session return is 2.20%, and the supplied evidence notes a long active dividend-increase streak. I exit if positive price behavior fails and its premium 21.38 P/E loses defensive justification.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: high · Horizon: quarters
Exit BMY because its 20-session return of -7.06% is materially weaker than the retained healthcare choices, while the portfolio can preserve healthcare exposure through names with firmer recent price evidence.
Recorded Sep 18, 2026, 8:08 AM EDT · Conviction: high · Horizon: weeks
Portfolio checks
The complete proposal passed the versioned universe, cash, concentration, and posture constraints without platform modification.
These checks cover portfolio constraints. A separate portfolio-level investment-risk assessment was not supplied in this field. Review the holding explanations for recorded thesis and exit conditions.
Ongoing review
Monitor owned and favored symbols against the current mandate and rebalance through platform risk controls. Monitor for mandate drift. Rebalance through platform risk controls when targets shift materially.
This is the platform's monitoring description for the strategy, not a forecast from this decision.
Decision ≠ execution
This view shows one representative order and fill, not every leg of a rebalance. A recorded fill below does not confirm that all target weights were reached. Open the strategy portfolio to inspect current holdings.
Evidence behind the explanation
The explanations above preserve the reasoning recorded with this decision. The record details below show processing and execution history. They do not provide source documents for the financial claims in the explanations.
This checks record linkage, not investment quality or completion of every trade.
These identify processing inputs and validation steps. They are not linked research sources.
Defensive Equity Blend cycle started by scheduled.
Defensive Equity Blend produced a canonical target-weight decision.
Created buy proposal for CI-USD.
Risk engine approved proposal 01M2T6W404DWFR8AFJBQ1R4G2V.
Queued buy order for CI-USD for MOO execution.
Defensive Equity Blend cycle completed with status pending_fill.
Defensive Equity Blend valuation snapshot recorded for agent_cycle_run 01M2T6T56V688ZCTF66YMJK5Y6.
Assumed MOO buy fill for CI-USD at the verified session open.
Simulated buy fill for CI-USD at the verified MOO session open.
Recorded balanced ledger entries for assumed MOO fill.